TWI740073B - Lactic acid bacteria crystal composition capable of promoting intestinal stem cell proliferation, antiviral, anti-inflammatory and anti-allergic effects and preparation method thereof. - Google Patents
Lactic acid bacteria crystal composition capable of promoting intestinal stem cell proliferation, antiviral, anti-inflammatory and anti-allergic effects and preparation method thereof. Download PDFInfo
- Publication number
- TWI740073B TWI740073B TW107140879A TW107140879A TWI740073B TW I740073 B TWI740073 B TW I740073B TW 107140879 A TW107140879 A TW 107140879A TW 107140879 A TW107140879 A TW 107140879A TW I740073 B TWI740073 B TW I740073B
- Authority
- TW
- Taiwan
- Prior art keywords
- acid bacteria
- lactic acid
- algae
- crystal composition
- fermentation
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
本發明提供一種藻類醱酵液包覆之乳酸菌晶體組合物,以純天然方式製程,使用醱酵生產的藻類醱酵液作為保護菌體的膠體來源,使此組合物具有耐胃酸和耐膽汁的能力,且此組合物以多種乳酸菌作為主體,能一次提供多種益菌的好處,同時藻類醱酵液膠體能協同乳酸菌作用,具有促進腸幹細胞增生、抗病毒、抗發炎和抗過敏功效的乳酸菌晶體組合物及其製備方法。 The present invention provides a lactic acid bacteria crystal composition coated with an algae fermented liquid, which is produced in a purely natural way, using the algae fermented liquid produced by fermented fermentation as a colloid source for protecting bacteria, so that the composition has the ability to resist gastric acid and bile And this composition takes a variety of lactic acid bacteria as the main body, which can provide the benefits of multiple beneficial bacteria at one time. At the same time, the algae fermented liquid colloid can cooperate with the lactic acid bacteria to promote the proliferation of intestinal stem cells, anti-virus, anti-inflammatory and anti-allergic lactic acid bacteria crystal combination物 and its preparation method.
乳酸菌對人體具有正面的效益,自1961年至1998年間,國際上已完成研究並發表在知名學術期刊的乳酸菌人體臨床試驗共計143件,受測人數達7,526人,均未有負面的結果報導,其中主要曾被報導的正面功效包括:(1)增進食品之營養品質,(2)促進維生素合成及酵素產生,(3)穩定腸道菌相,並去除腸內病菌,(4)產生抗菌物質,增強宿主免疫力,(5)降低膽固醇含量,(6)降低大腸癌之風險,(7)抑制腫瘤等。 Lactic acid bacteria have a positive effect on the human body. From 1961 to 1998, a total of 143 human clinical trials of lactic acid bacteria have been completed and published in well-known academic journals. The number of people tested reached 7,526, and there were no negative results reported. The main positive effects that have been reported include: (1) improve the nutritional quality of food, (2) promote vitamin synthesis and enzyme production, (3) stabilize the intestinal flora and remove intestinal bacteria, (4) produce antibacterial substances , Enhance host immunity, (5) reduce cholesterol content, (6) reduce the risk of colorectal cancer, (7) inhibit tumors, etc.
最常被科學家用來測試的乳酸菌為嗜酸乳桿菌(Lactobacillus acidophilus,即俗稱的A菌),其次為凱氏乳桿菌(Lactobacillus casei,即俗稱的C菌),其他較常被測試的菌尚有雙歧桿菌(Bifidobacterium sp.,即俗稱的B菌,又稱雙叉桿菌或比菲德氏菌)、保加利亞乳桿菌(Lactobacillus bulgaricus)、嗜高溫鏈球菌(Streptococcus thermophilus),後兩者即是由鮮乳製造優酪乳過程中所必需添加的兩株乳酸菌。 The most commonly used lactic acid bacteria to be tested by scientists is Lactobacillus acidophilus (commonly known as bacteria A), followed by Lactobacillus casei (commonly known as bacteria C), and other bacteria that are more commonly tested are still There are Bifidobacterium (Bifidobacterium sp., commonly known as B bacteria, also known as Bifidobacterium or Bifidobacterium), Lactobacillus bulgaricus, Streptococcus thermophilus, and the latter two are Two strains of lactic acid bacteria must be added in the process of making yogurt from fresh milk.
但乳酸菌產品經過腸胃道消化後容易失去活性,部分菌種能到達腸道卻不具有多種功效,目前已知菌種進行改良後能具有耐酸鹼能力,也具有生理活性功效,但部分科學家仍對菌種改良存在疑慮。因此乳酸菌普遍有不穩定,無法耐熱耐酸的缺點,會隨環境變化、保存條件不佳導致功效降低,必須低溫冷藏,如何增加乳酸菌產品的安定性和耐酸鹼能力來達到其功效是急需解決的問題。 However, lactic acid bacteria products are prone to lose their activity after digestion in the gastrointestinal tract. Some bacteria can reach the intestines but do not have multiple functions. It is currently known that the modified bacteria can have acid and alkali resistance and also have physiological activities. However, some scientists still There are doubts about strain improvement. Therefore, lactic acid bacteria generally have the shortcomings of instability, inability to heat and acid, will change with environmental changes and poor storage conditions, resulting in reduced efficacy. They must be refrigerated at low temperatures. How to increase the stability and acid and alkali resistance of lactic acid bacteria products to achieve their efficacy is an urgent need to solve problem.
依據文獻The Anti-Inflammatory Effect of Algae-Derived Lipid Extracts on Lipopolysaccharide(LPS)-Stimulated Human THP-1 Macrophages.Marine drugs.Vol 13,P5402-5424,從Koozeh奶酪中分離的乳酸桿菌的抗菌,抗酸和膽汁耐受性研究中,從三組乳酸桿菌(如:植物乳桿菌,乾酪乳桿菌和德氏乳桿菌)分離出二十八株的乳桿菌菌株來進行耐膽汁能力、酸耐受能力和抗菌性能,結果發現只有一種分離物即乾酪乳桿菌可以耐受酸和膽汁鹽並具有抗單核細胞增生的抗菌活性,可以考慮做為天然益生菌產品,但仍須額外的測試來證明,可見一般乳酸菌不具有耐膽鹼能力和耐酸能力,需要發花費很多時間來篩選和測試,此嚴重局限了乳酸菌的應用。 According to the literature The Anti-Inflammatory Effect of Algae-Derived Lipid Extracts on Lipopolysaccharide(LPS)-Stimulated Human THP-1 Macrophages.Marine drugs.Vol 13,P5402-5424, the antibacterial, acid-fast and antibacterial properties of Lactobacillus isolated from Koozeh cheese In the study of bile tolerance, 28 Lactobacillus strains were isolated from three groups of Lactobacillus (such as Lactobacillus plantarum, Lactobacillus casei and Lactobacillus delbrueckii) for bile tolerance, acid tolerance and antibacterial Performance, it turns out that only one isolate, Lactobacillus casei, can tolerate acid and bile salts and has anti-monocytic proliferation antibacterial activity. It can be considered as a natural probiotic product, but additional tests are still needed to prove it. Lactic acid bacteria do not have the ability to tolerate choline and acid, and it takes a lot of time to screen and test, which severely limits the application of lactic acid bacteria.
另一藻類研究中藻類中的多醣及多酚物質具有抗氧化、抗癌、抗凝血、抗發炎、抗病毒、抗高血脂症等功效,為了取得這些活性物質,產業界通常使用熱水、溶劑、酸水解、酵素水解等萃取法,但這些萃取方式通常伴隨著一些限制因子,包括:高成本、流程複雜及溶劑殘存毒性問題。另有研究發現藻類醱酵過程能釋放出更多的藻類活性成分,如:一般萃取法不易取得的特有海藻胜肽、胺基酸、多酚類化合物都可透過醱酵過程充分釋出,讓產品中的營養素更豐富,且經長時間醱酵作用,可將海藻中的營養素分解成小分子狀態,更利於生物吸收利用,但通常藻類多醣被作為主原料,在功效上並無益生菌可改善腸道、修復黏膜組織等功效。 In another study of algae, the polysaccharides and polyphenols in algae have anti-oxidation, anti-cancer, anti-coagulation, anti-inflammatory, anti-viral, and anti-hyperlipidemia effects. In order to obtain these active substances, the industry usually uses hot water, Solvent, acid hydrolysis, enzyme hydrolysis and other extraction methods, but these extraction methods are usually accompanied by some limiting factors, including: high cost, complicated process and residual toxicity of solvents. Another study found that the algae fermentation process can release more algae active ingredients, such as: the unique seaweed peptides, amino acids, and polyphenol compounds that are not easily obtained by general extraction methods can be fully released through the fermentation process, so that The nutrients in the product are richer, and after a long time of fermentation, the nutrients in the seaweed can be decomposed into small molecules, which is more conducive to biological absorption and utilization, but usually algae polysaccharides are used as the main raw material, and there are no probiotics in terms of efficacy. Improve intestines, repair mucosal tissues and other functions.
因此發展出適合一般大眾使用且具有耐酸和耐膽鹼能力的乳酸菌晶體組合物,且保有抗發炎、抗病毒及修復黏膜的功效是現階段最重要急需解決的問題。 Therefore, the development of a lactic acid bacteria crystal composition that is suitable for the general public and has acid and choline resistance, and maintains the effects of anti-inflammatory, anti-virus and mucosal repair is the most important problem that needs to be solved at this stage.
為解決上述的問題,本發明以純天然方式製程,以醱酵生產的藻類醱酵液作為保護菌體的膠體來源,使乳酸菌具有耐酸和耐膽鹼的能力且沒有使用上食用的安全疑慮,且本發明以多種乳酸菌作為主體,能一次提供多種益菌的好處,同時藻類醱酵液膠體能協同乳酸菌作用,使功效同時具促進腸幹細胞增生、抗病毒、抗發炎和抗過敏。 In order to solve the above-mentioned problems, the present invention adopts a purely natural process, and uses the algae fermented liquid produced by fermenting as a source of colloid to protect the bacteria, so that the lactic acid bacteria have the ability to resist acid and choline and there is no doubt about the safety of use and food, and The present invention takes multiple lactic acid bacteria as the main body and can provide the benefits of multiple beneficial bacteria at one time. At the same time, the algae fermented liquid colloid can synergize the action of lactic acid bacteria, so that the effect can simultaneously promote intestinal stem cell proliferation, anti-virus, anti-inflammatory and anti-allergic.
本發明一實施例中一種具有耐酸和耐膽鹼能力之乳酸菌晶體組合物,其中該組合物包含:乳酸菌和藻類醱酵液,藻類醱酵液係為膠體結構,其包覆於該乳酸菌外,形成乳酸菌晶體外殼。 In an embodiment of the present invention, a lactic acid bacteria crystal composition with acid and choline resistance, wherein the composition comprises: lactic acid bacteria and algae fermented liquid, the algae fermented liquid is a colloidal structure, which is coated outside the lactic acid bacteria, The lactic acid bacteria crystal shell is formed.
本發明一實施例中,所述之乳酸菌晶體組合物,其中該膠體結構包含醣分子,該醣分子係為α葡聚醣或β葡聚醣降解後產生之小分子醣,該醣分子包覆該乳酸菌形成該乳酸菌晶體外殼。 In an embodiment of the present invention, the lactic acid bacteria crystal composition, wherein the colloidal structure contains sugar molecules, the sugar molecules are small molecule sugars produced after degradation of α-glucan or β-glucan, and the sugar molecules are coated The lactic acid bacteria form the lactic acid bacteria crystal shell.
本發明一實施例中,所述之乳酸菌晶體組合物,其中該乳酸菌包含Lactobacillus rhamnosus、Lactobacillus plantarum、Lactobacillus acidophilus或Lactobacillus sporogenes菌株。 In an embodiment of the present invention, the lactic acid bacteria crystal composition, wherein the lactic acid bacteria comprise Lactobacillus rhamnosus , Lactobacillus plantarum , Lactobacillus acidophilus or Lactobacillus sporogenes strains.
本發明一實施例中,所述之乳酸菌晶體組合物,其中該乳酸菌的混合比例為Lactobacillus rhamnosus含量為3×108CFU/g~5×108CFU/g、Lactobacillus plantarum含量為3×108CFU/g~5×108CFU/g、Lactobacillus acidophilus含量為3×108CFU/g~5×108CFU/g、和Lactobacillus sporogenes含量為3×108CFU/g~5×108CFU/g。 In an embodiment of the present invention, in the lactic acid bacteria crystal composition, the mixing ratio of the lactic acid bacteria is that the content of Lactobacillus rhamnosus is 3×10 8 CFU/g~5×10 8 CFU/g, and the content of Lactobacillus plantarum is 3×10 8 CFU/g~5×10 8 CFU/g, Lactobacillus acidophilus content is 3×10 8 CFU/g~5×10 8 CFU/g, and Lactobacillus sporogenes content is 3×10 8 CFU/g~5×10 8 CFU /g.
本發明一實施例中,所述之乳酸菌晶體組合物,其中該藻類醱酵液包含海木耳、石菜花、石蓴、青絲藻、海葡萄或葛仙米藻之醱酵液,在一較佳實施例中,該藻類醱酵係為海木耳醱酵液。 In an embodiment of the present invention, the lactic acid bacteria crystal composition, wherein the algae fermented liquid contains sea fungus, agaric, ulva, chlorophyllum, sea grape or pueraria lobata fermented fermented liquid, a preferred In the embodiment, the algae ferment system is sea fungus fermented liquid.
本發明一實施例中,所述之乳酸菌晶體組合物,其中該藻類醱酵液與該乳酸菌的混合體積比為50:1~70:1。 In an embodiment of the present invention, in the lactic acid bacteria crystal composition, the mixing volume ratio of the algae fermented liquid and the lactic acid bacteria is 50:1 to 70:1.
本發明一實施例中,所述之乳酸菌晶體組合物,其中該藻類醱酵液與該乳酸菌的混合體積比最佳為60:1。 In an embodiment of the present invention, in the lactic acid bacteria crystal composition, the mixing volume ratio of the algae fermented liquid and the lactic acid bacteria is preferably 60:1.
本發明一實施例中一種具有耐酸和耐膽鹼能力之乳酸菌晶體組合物的功效應用,其中該功效包含促進腸幹細胞增生、抗病毒、抗發炎和抗過敏等功效。 According to an embodiment of the present invention, a lactic acid bacteria crystal composition with acid and choline resistance is used for the efficacy application, wherein the efficacy includes the effects of promoting intestinal stem cell proliferation, antiviral, anti-inflammatory and anti-allergic effects.
本發明一實施例中,一種用於製備該具有耐酸和耐膽鹼能力 之乳酸菌晶體組合物之藻類醱酵液的方法,為:(1)初萃醱酵步驟:將藻類壓榨後,添加A菌進行90天初萃醱酵;(2)複合醱酵步驟:添加B酵母菌和C乳酸菌,進行390天複合醱酵;(3)儲存醱酵步驟:加入D醋酸菌,進行30天醱酵;以及(4)螯合醱酵步驟:添加鎂與鈣化合物,進行30天醱酵,利用菌體將鈣、鎂元素轉換為有機態;醱酵過程中菌種添加為107~108CFU/ml,接種量為體積1.5%;醱酵溫度控制在26-32℃。 In one embodiment of the present invention, a method for preparing the algae fermented liquid of the acid-resistant and choline-resistant lactic acid bacteria crystal composition is: (1) the initial extraction ferment step: after the algae is squeezed, A is added (2) Compound fermentation step: add B yeast and C lactic acid bacteria for 390 days compound fermentation; (3) Storage fermentation step: add D acetic acid bacteria for 30 days fermentation And (4) Chelated fermentation step: add magnesium and calcium compounds, carry out 30-day fermentation, and use bacteria to convert calcium and magnesium into organic state; during the fermentation process, the bacteria are added to 10 7 ~ 10 8 CFU /ml, the inoculum volume is 1.5% by volume; the fermentation temperature is controlled at 26-32℃.
本發明一實施例中,製備該具有耐酸和耐膽鹼能力之乳酸菌晶體組合物之藻類醱酵液的方法,其中乳酸菌濃度108CFU/ml,接種量為體積1.5%,酵母菌濃度107CFU/ml,接種量為體積1.5%,菌數量必須足以成為優勢菌種。 In one embodiment of the present invention, the method for preparing the algae lactic acid bacterium having resistance to acid and choline ability of the crystalline composition of the fermentation broth Po, wherein the concentration of lactic acid 10 8 CFU / ml, was inoculated in an amount of 1.5% by volume, a concentration of 107 yeast CFU/ml, the inoculum volume is 1.5% by volume, and the number of bacteria must be sufficient to become the dominant bacteria species.
本發明一實施例中,製備該具有耐酸和耐膽鹼能力之乳酸菌晶體組合物之藻類醱酵液的方法,其中於初萃醱酵步驟加入的A菌為酵母菌Saccharomyces cerevisiae。 In an embodiment of the present invention, the method for preparing the algae fermented liquid of the acid-resistant and choline-resistant lactic acid bacteria crystal composition, wherein the bacteria A added in the initial extraction ferment step is the yeast Saccharomyces cerevisiae .
本發明一實施例中,製備該具有耐酸和耐膽鹼能力之乳酸菌晶體組合物之藻類醱酵液的方法,其中於複合醱酵步驟添加之B酵母菌為Saccharomycopsisfibufigera、Pichia membramefaciens、Schizosaccharomyespombe酵母菌。 In one embodiment of the present invention, the method for preparing the algae fermented liquid of the lactic acid bacteria crystal composition with acid and choline resistance ability, wherein the B yeast added in the compound fermenting step is Saccharomycopsisfibufigera , Pichia membramefaciens , Schizosaccharomyespombe yeast.
本發明一實施例中,製備該具有耐酸和耐膽鹼能力之乳酸菌晶體組合物之藻類醱酵液的方法,其中於複合醱酵步驟添加之C乳酸菌為Lactobacillus plantarum、Lactobacillus delbrueckii、Lactococcuslactis、 Lactococcusacidophillus、Bifidobacterium bifidum乳酸菌。 In an embodiment of the present invention, the method for preparing the algae fermentation liquid of the lactic acid bacteria crystal composition with acid and choline resistance ability, wherein the C lactic acid bacteria added in the compound fermentation step are Lactobacillus plantarum , Lactobacillus delbrueckii , Lactococcuslactis , Lactococcus acidophillus, Bifidobacterium bifidum lactic acid bacteria.
本發明一實施例中,製備具有耐酸和耐膽鹼能力之乳酸菌晶體組合物之藻類醱酵液的方法,其中於儲存醱酵步驟加入之D醋酸菌為Acetobacterhansenii、Acetobacterxylinum、Acetobactorsuboxydans醋酸菌。 In an embodiment of the present invention, the method for preparing an algae fermentation liquid of a lactic acid bacteria crystal composition with acid and choline resistance, wherein the D acetic acid bacteria added in the storage fermentation step are Acetobacterhansenii , Acetobacterxylinum , Acetobactor suboxydans acetic acid bacteria.
本發明一實施例中,製備具有耐酸和耐膽鹼能力之乳酸菌晶體組合物的方法,包括:(1)提供一藻類醱酵液,該藻類醱酵液製造方法如先前製程所述製造;(2)提供一乳酸菌,該乳酸菌係選自由Lactobacillus rhamnosus、Lactobacillus plantarum、Lactobacillus acidophilus和Lactobacillus sporogenes所組成之群組;(3)混合步驟,將該藻類醱酵液與該乳酸菌以60:1體積比混合;以及(4)高速乳化步驟,將步驟(3)所完成的混合溶液經高速乳化頭以1000~3000rpm速度乳化後,使已完成醱酵製程的藻類醱酵液膠體結構包覆於該乳酸菌外層,形成乳酸菌晶體外殼,完成該乳酸菌晶體組合物。 In an embodiment of the present invention, a method for preparing a lactic acid bacteria crystal composition with acid and choline resistance includes: (1) providing an algae fermented liquid, and the production method of the algae fermented liquid is as described in the previous process; 2) Provide a lactic acid bacteria, the lactic acid bacteria is selected from the group consisting of Lactobacillus rhamnosus , Lactobacillus plantarum , Lactobacillus acidophilus and Lactobacillus sporogenes ; (3) mixing step, mixing the algae fermented liquid with the lactic acid bacteria in a volume ratio of 60:1 And (4) a high-speed emulsification step. After the mixed solution completed in step (3) is emulsified at a speed of 1000~3000rpm through a high-speed emulsifying head, the algae fermented liquid colloidal structure that has completed the fermentation process is coated on the outer layer of the lactic acid bacteria , The lactic acid bacteria crystal shell is formed, and the lactic acid bacteria crystal composition is completed.
藻類膠體結構以醣分子為主,醣分子來源為葡聚醣降解後產生之小分子醣,乳化階段時,以包覆或鍵結方式在乳酸菌周為形成外殼,產生乳酸菌晶體;該乳酸菌晶體組合物具有耐酸和耐膽鹼能力,促進腸幹細胞增生、抗病毒、抗發炎和抗過敏功效。 The structure of algae colloid is dominated by sugar molecules. The source of sugar molecules is the small molecule sugars produced by the degradation of glucan. During the emulsification stage, a shell is formed around the lactic acid bacteria by coating or bonding to produce lactic acid bacteria crystals; the lactic acid bacteria crystal combination It has acid and choline resistance, promotes the proliferation of intestinal stem cells, antiviral, anti-inflammatory and anti-allergic effects.
第1圖顯示藻類醱酵液包覆於乳酸菌之晶體外殼組合物。 Figure 1 shows the crystal shell composition of lactic acid bacteria coated with algae fermented liquid.
第2圖顯示乳酸菌晶體組合物以複式顯微鏡成像的攝影圖,放大倍率為400倍。 Figure 2 shows a photograph of the lactic acid bacteria crystal composition imaged by a compound microscope with a magnification of 400 times.
第3圖顯示乳酸菌的耐酸能力試驗,實驗分成兩組:(1)四株乳酸菌混合物組和(2)四株乳酸菌+藻類醱酵液之晶體組合物,數值表示為平均值±標準差,** P<0.01表示在耐酸能力試驗中(2)四株乳酸菌+藻類醱酵液之晶體組合物與(1)四種乳酸桿菌菌株的數值相比具有顯著差異。證實乳酸菌未經處理,透過鹽酸模擬胃酸破壞後,存活率大幅降低,但經藻類醱酵液包覆之乳酸菌晶體組合物,即便通過胃酸破壞,仍然保有良好存活率,即透過藻類醱酵液包覆結構,可提供乳酸菌抗酸蝕能力。 Figure 3 shows the acid tolerance test of lactic acid bacteria. The experiment is divided into two groups: (1) a mixture of four lactic acid bacteria and (2) a crystal composition of four lactic acid bacteria + algae fermentation solution. The values are expressed as mean ± standard deviation, * * P<0.01 means that (2) the crystal composition of the four lactic acid bacteria + algae fermented liquid has a significant difference compared with (1) the value of the four lactic acid bacteria strains in the acid tolerance test. It is confirmed that the survival rate of lactic acid bacteria is greatly reduced after being destroyed by simulating gastric acid through hydrochloric acid without treatment. However, the lactic acid bacteria crystal composition coated with algae fermented liquid still retains a good survival rate even if it is destroyed by gastric acid, that is, through the algae fermented liquid package. Cover structure, can provide lactic acid bacteria resistance to acid corrosion.
第4圖顯示乳酸菌的耐膽鹼能力試驗,實驗分成兩組:(1)四株乳酸菌混合物組和(2)四株乳酸菌+藻類醱酵液結晶體組合物,數值表示為平均值±標準差,** *P<0.001表示耐膽鹼能力試驗中(2)四株乳酸菌+藻類醱酵液結晶體組合物與(1)四種乳酸桿菌菌株的數值相比具有顯著差異。 Figure 4 shows the choline tolerance test of lactic acid bacteria. The experiment is divided into two groups: (1) four strains of lactic acid bacteria mixture group and (2) four strains of lactic acid bacteria + algae fermentation liquid crystal composition. The values are expressed as mean ± standard deviation. ** * P<0.001 indicates that (2) the four lactic acid bacteria + algae fermentation liquid crystal composition in the choline tolerance test is significantly different from (1) the values of the four lactic acid bacteria strains.
第5圖顯示乳酸菌的腸幹細胞增生試驗,實驗分成五組樣品,分別為:(1)Control-對照組、(2)四株乳酸菌混合物、(3)藻類萃取物、(4)藻類醱酵液以及(5)四株乳酸菌+藻類醱酵液晶體組合物,數值表示為平均值±標準差,*P<0.05、**P<0.01、***P<0.001表示腸幹細胞存活率試驗中和控制組數值相比具有顯著差異。結果證實乳酸菌未經處理,透過Oxoid模擬膽鹼破壞後,存活率大幅降低,但經藻類醱酵液包覆之乳酸菌晶體組合物,即便通過膽鹼破壞,仍然保有良好存活率。 Figure 5 shows the intestinal stem cell proliferation test of lactic acid bacteria. The experiment is divided into five groups of samples: (1) Control-control group, (2) a mixture of four lactic acid bacteria, (3) algae extract, (4) algae fermented liquid And (5) Four strains of lactic acid bacteria + algae fermented liquid crystal composition, the value is expressed as the mean ± standard deviation, * P<0.05, ** P<0.01, *** P<0.001 indicates that the intestinal stem cell survival rate test neutral Compared with the control group, there are significant differences. The results confirmed that the survival rate of lactic acid bacteria without treatment was greatly reduced after being destroyed by Oxoid to simulate choline, but the lactic acid bacteria crystal composition coated with algae fermented liquid, even if destroyed by choline, still maintained a good survival rate.
第6圖顯示乳酸菌的抗病毒試驗,實驗分成六組樣本,分別 為:(1)Control-對照組、(2)Virus-攻毒組、(3)四株乳酸菌混合物-攻毒組、(4)藻類萃取物-攻毒組、(5)藻類醱酵液-攻毒組以及(6)四株乳酸菌+藻類醱酵液結晶體-攻毒組。數值表示為平均值±標準差,*P<0.05、**P<0.01、***P<0.001表示抗病毒功效試驗中與(2)Virus-攻毒組數值相比具有顯著差異;結果顯示一般乳酸菌經混合後,對於vero腎上皮細胞的保護力已有顯著性,可保護vero腎上皮細胞免於病毒感染;藻類萃取液經醱酵後則能提升細胞的保護力;乳酸菌以藻類醱酵液包覆後之晶體組合物則能提供最高的保護力,達到最高顯著性;對病毒抑制力也具有效果,也以(6)四株乳酸菌+藻類醱酵液結晶體-攻毒組乳酸菌經藻類醱酵液包覆後具有最高抑制效果。 Figure 6 shows the antiviral test of lactic acid bacteria. The experiment is divided into six groups of samples: (1) Control-control group, (2) Virus-challenge group, (3) four lactic acid bacteria mixture-challenge group, (4) ) Algae extract-challenge group, (5) algae fermentation liquid-challenge group and (6) four lactic acid bacteria + algae fermentation liquid crystal-challenge group. Values are expressed as mean ± standard deviation, * P<0.05, ** P<0.01, *** P<0.001 indicates that there is a significant difference in the antiviral efficacy test compared with (2) Virus-challenge group value; the results show After mixing, the general lactic acid bacteria have a significant protective effect on the vero renal epithelial cells, which can protect the vero renal epithelial cells from virus infection; the algae extract can enhance the protection of the cells after being fermented; the lactic acid bacteria are fermented with algae The crystal composition coated with liquid can provide the highest protection and reach the highest significance; it also has an effect on virus inhibition. Also, (6) four strains of lactic acid bacteria + algae fermentation liquid crystals-challenge group lactic acid bacteria through algae fermentation It has the highest inhibitory effect after being coated with ferment liquid.
第7圖顯示抗發炎的人體試驗,隨機12名受測者,依照建議方式每日服用,持續5周,於每周填寫回饋問卷,統計評分,得分越高表示改善情形越佳。(N=12) Figure 7 shows an anti-inflammatory human trial. 12 subjects were randomly taken according to the recommended method every day for 5 weeks. The feedback questionnaire was filled out every week and the score was calculated. The higher the score, the better the improvement. (N=12)
藻類醱酵液在醱酵製程中添加鎂與鈣,經540天,由4株酵母菌、5株乳酸菌、3株醋酸菌共12株菌進行醱酵,將鎂與鈣轉換為有機態,再加入乳酸菌,使藻類醱酵液包覆於乳酸菌外層後提供生物利用。 The algae fermented liquid is fermented with magnesium and calcium in the fermenting process. After 540 days, 12 strains of 4 yeasts, 5 lactic acid bacteria, and 3 acetic bacteria are fermented to convert the magnesium and calcium into an organic state. Lactic acid bacteria are added to make the algae fermented liquid coat the outer layer of lactic acid bacteria to provide biological utilization.
本發明藻類醱酵液製作流程分為三階段植入菌種,共四個醱酵階段,階段1:初萃醱酵,將藻類壓榨後,添加1株酵母菌Saccharomyces cerevisiae進行90天初萃醱酵;階段2:複合醱酵階段,再添加3株酵母菌如:Saccharomycopsisfibufigera、Pichia membramefaciens、 Schizosaccharomyespombe,和5株乳酸菌如:Lactobacillus plantarum、Lactobacillus delbrueckii、Lactococcuslactis、Lactococcusacidophillus、Bifidobacterium bifidum,進行390天複合醱酵;階段3:儲存醱酵階段,加入3株醋酸菌如:Acetobacterhansenii、Acetobacterxylinum、Acetobactorsuboxydans,進行30天醱酵;階段4:螯合醱酵階段中添加鎂與鈣化合物,進行30天醱酵,利用菌體將鈣、鎂元素轉換為有機態,醱酵過程中菌種添加為107~108CFU/ml,接種量為體積1.5%,醱酵溫度控制在26-32℃,製作出藻類醱酵液。 The production process of the algae fermented liquid of the present invention is divided into three stages of implantation of strains, a total of four fermenting stages, stage 1: initial extraction ferment, after the algae is squeezed, 1 strain of yeast Saccharomyces cerevisiae is added for 90 days of initial extraction yeast; stage 2: composite Po fermentation stage, yeast such as add 3: Saccharomycopsisfibufigera, Pichia membramefaciens, Schizosaccharomyespombe, such as lactic acid and 5: Lactobacillus plantarum, Lactobacillus delbrueckii, Lactococcuslactis , Lactococcusacidophillus, Bifidobacterium bifidum, composite Po fermentation for 390 days Phase 3: Storage fermentation stage, add 3 strains of acetic acid bacteria such as: Acetobacterhansenii , Acetobacterxylinum , Acetobactorsuboxydans , for 30 days fermentation; Phase 4: Chelate fermentation stage, add magnesium and calcium compounds, for 30 days fermentation, use The bacteria convert the calcium and magnesium elements into organic state. During the fermentation process, the bacteria are added at 10 7 ~ 10 8 CFU/ml, the inoculation amount is 1.5% by volume, and the fermentation temperature is controlled at 26-32°C to produce algae broth. Fermented liquid.
本發明製備藻類醱酵液包覆於乳酸菌晶體外殼之組合物的方法,步驟1:一混合步驟,將已完成醱酵製程的藻類醱酵液與1.5%的四種乳酸菌溶液(如:Lactobacillus rhamnosus、Lactobacillus plantarum、Lactobacillus acidophilus、Lactobacillus sporogenes等比例混合液)混合以及步驟2:一高速乳化步驟,將該混合溶液經高速乳化頭乳化後,使已完成醱酵製程的藻類醱酵液膠體結構包覆於該乳酸菌外層,形成乳酸菌晶體外殼,完成該乳酸菌晶體組合物。該乳酸菌晶體組合物具有耐酸和耐膽鹼能力,促進腸幹細胞增生、抗病毒、抗發炎和抗過敏功效。 The method of the present invention for preparing a composition in which an algae fermented liquid is coated on a lactic acid bacteria crystal shell, step 1: a mixing step, the algae fermented liquid that has completed the fermenting process and 1.5% of four lactic acid bacteria solutions (such as: Lactobacillus rhamnosus , Lactobacillus plantarum , Lactobacillus acidophilus , Lactobacillus sporogenes, etc.) mixing and step 2: a high-speed emulsification step, the mixed solution is emulsified by a high-speed emulsifying head, so that the algae fermented liquid that has completed the fermentation process is coated with the colloidal structure On the outer layer of the lactic acid bacteria, a lactic acid bacteria crystal shell is formed to complete the lactic acid bacteria crystal composition. The lactic acid bacteria crystal composition has the ability of acid resistance and choline resistance, promotes the proliferation of intestinal stem cells, has antiviral, anti-inflammatory and anti-allergic effects.
將耐酸和耐膽鹼實驗分成兩組:(1)四株乳酸菌混合物、 (2)四株乳酸菌+藻類醱酵液結晶體組合物 The acid resistance and choline resistance experiments are divided into two groups: (1) a mixture of four lactic acid bacteria, (2) Four strains of lactic acid bacteria + algae fermented liquid crystal composition
將四株乳酸菌分別培養於MRS培養基中,於37℃培養48小時後各取0.1ml菌液混合,加入5N HCl調整pH值至2,培養在37℃四小時後序列稀釋並塗盤,培養24小時後計數菌落;另將四株乳酸菌+藻類醱酵液結晶組合物培養於MRS培養基中,於37℃培養48小時後取0.4ml,加入5N HCl調整pH值至2,培養在37℃四小時後序列稀釋並塗盤,培養24小時後計數菌落。存活之乳酸菌能正常行成菌落,藉此評估活菌數。 Four strains of lactic acid bacteria were cultured in MRS medium. After culturing at 37°C for 48 hours, each 0.1ml of the bacterial solution was mixed, and 5N HCl was added to adjust the pH to 2. After culturing at 37°C for four hours, the sequence was diluted and coated, and cultivated for 24 hours. Count the colonies after hours; in addition, four strains of lactic acid bacteria + algae fermentation broth crystallization composition were cultured in MRS medium, cultured at 37°C for 48 hours, then 0.4ml was taken, and 5N HCl was added to adjust the pH to 2, and cultured at 37°C for four hours The post-sequence was diluted and plated, and the colonies were counted after 24 hours of cultivation. The surviving lactic acid bacteria can form colonies normally, so as to evaluate the number of viable bacteria.
耐酸能力試驗結果如第3圖所示,顯示(2)四株乳酸菌+藻類醱酵液晶體組合物之耐酸的活菌數顯著高於(1)四株乳酸菌混合物(**P<0.01),證實乳酸菌未經處理,透過HCl模擬胃酸破壞後,存活率大幅降低,但經藻類醱酵液包覆之乳酸菌晶體組合物,即便通過胃酸破壞,仍然保有良好存活率,即透過藻類醱酵液包覆結構,可提供乳酸菌抗酸蝕能力。 The results of the acid tolerance test are shown in Figure 3, showing that (2) the number of viable acid-resistant bacteria of the four lactic acid bacteria + algae fermented liquid crystal composition is significantly higher than (1) the four lactic acid bacteria mixture ( ** P<0.01), It is confirmed that the survival rate of lactic acid bacteria is greatly reduced after being destroyed by HCl to simulate the destruction of gastric acid without treatment. However, the lactic acid bacteria crystal composition coated with algae fermented liquid still maintains a good survival rate even if it is destroyed by gastric acid, that is, through the algae fermented liquid package Cover structure, can provide lactic acid bacteria resistance to acid corrosion.
將四株乳酸菌分別培養於MRS培養基中,於37℃培養48小時後各取0.1ml菌液混合,加入Oxoid飽和溶液(Oxoid為膽汁萃取物),添加濃度為0.3%,培養在37℃四小時後序列稀釋並塗盤,培養24小時後計數菌落;另將四株乳酸菌+藻類醱酵液結晶體培養於MRS培養基中,於37℃培養48小時後取0.4ml,加入Oxoid飽和溶液(Oxoid為膽汁萃取物),添加濃度為0.3%,培養在37℃四小時後序列稀釋並塗盤,培養24小時後計數菌落。存活之乳酸菌能正常行成菌落,藉此評估活菌數。 Four strains of lactic acid bacteria were cultured in MRS medium. After culturing at 37℃ for 48 hours, each 0.1ml of the bacterial solution was mixed, and Oxoid saturated solution (Oxoid is bile extract) was added at a concentration of 0.3%, and cultured at 37℃ for four hours The post-sequence was diluted and plated, and the colonies were counted after 24 hours of culture; 4 strains of lactic acid bacteria + algae fermented liquid crystals were cultured in MRS medium, incubated at 37°C for 48 hours, 0.4ml was taken, and Oxoid saturated solution (Oxoid is bile) Extract), added at a concentration of 0.3%, cultured at 37°C for four hours and then serially diluted and plated. After 24 hours of culture, the colonies were counted. The surviving lactic acid bacteria can form colonies normally, so as to evaluate the number of viable bacteria.
耐膽鹼能力試驗結果如第4圖所示,顯示(2)四株乳酸菌+藻類醱酵液晶體組合物之耐膽鹼的活菌數顯著高於(1)四株乳酸菌混合物(***P<0.001),證實乳酸菌未經處理,透過Oxoid模擬膽鹼破壞後,存活率大幅降低,但經藻類醱酵液包覆之乳酸菌晶體組合物,即便通過膽鹼破壞,仍然保有良好存活率,即透過藻類醱酵液包覆結構,可提供乳酸菌抗膽鹼能力。 The results of the choline tolerance test are shown in Figure 4, showing that (2) the number of viable choline-resistant bacteria of the four lactic acid bacteria + algae fermented liquid crystal composition is significantly higher than (1) the four lactic acid bacteria mixture ( *** P<0.001), it was confirmed that the survival rate of lactic acid bacteria without treatment was greatly reduced after simulating choline destruction by Oxoid, but the lactic acid bacteria crystal composition coated with algae ferment solution, even if destroyed by choline, still maintained a good survival rate. That is, through the algae fermented liquid coating structure, it can provide the anticholinergic ability of lactic acid bacteria.
將腸幹細胞增生實驗分成五組樣本,分別為: The intestinal stem cell proliferation experiment is divided into five groups of samples, namely:
(1)Control-對照組 (1) Control-control group
(2)四株乳酸菌混合物 (2) Mixture of four lactic acid bacteria
(3)藻類萃取物 (3) Algae extract
(4)藻類醱酵液 (4) Algae fermented liquid
(5)四株乳酸菌+藻類醱酵液晶體組合物 (5) Four strains of lactic acid bacteria + algae fermented liquid crystal composition
ISCs為腸道幹細胞,分別將樣本(1)Control-對照組、(2)四株乳酸菌混合物、(3)藻類萃取物(未經藻類醱酵)、(4)藻類醱酵液和(5)四株乳酸菌+藻類醱酵液晶體組合物與SCIs腸道幹細胞共同培養,分析各樣本對腸道幹細胞增生之能力,ISCs腸道幹細胞可分化為黏膜細胞、表皮細胞,達到傷口修復、修補黏膜組織等能力。試驗將ISCs腸道幹細胞種於96孔盤中,50,000cell/well,培養24小時後更換培養基(分別含200μg/ml各樣本與不含樣本),培養24與48小時,以MTT assay進行細胞存活率試驗。 ISCs are intestinal stem cells. The samples are (1) Control-control group, (2) a mixture of four lactic acid bacteria, (3) algae extract (without algae fermentation), (4) algae fermentation solution and (5) Four strains of lactic acid bacteria + algae fermented liquid crystal composition were co-cultured with SCIs intestinal stem cells to analyze the ability of each sample to proliferate intestinal stem cells. ISCs intestinal stem cells can differentiate into mucosal cells and epidermal cells to achieve wound repair and repair mucosal tissue And other capabilities. In the experiment, ISCs intestinal stem cells were planted in 96-well plates, 50,000cell/well, cultured for 24 hours and then replaced with medium (with 200μg/ml samples and no samples respectively), cultured for 24 and 48 hours, and survived by MTT assay Rate test.
乳酸菌晶體組合物的腸幹細胞增生試驗結果如圖5所示,顯 示在24小時及48小時共培養,乳酸菌未包覆實增生率最高達約15%,在(3)藻類萃取液與(2)乳酸菌混合物的增生率相似;但藻類經醱酵後之(4)藻類醱酵液能提升些微增生能力約50%;以及(5)乳酸菌與藻類醱酵液結合形成晶體組合物後,增生效果達到最高約75%,具有顯著差異,表示乳酸菌與藻類醱酵液有加乘效果。 The results of the intestinal stem cell proliferation test of the lactic acid bacteria crystal composition are shown in Figure 5, which shows It is shown that at 24 hours and 48 hours of co-cultivation, the uncoated lactic acid bacteria proliferation rate is up to about 15%. The proliferation rate of (3) the algae extract is similar to (2) the lactic acid bacteria mixture; but the algae is fermented (4) ) The algae fermented liquid can increase the micro-proliferation ability by about 50%; and (5) After the lactic acid bacteria and the algae fermented liquid are combined to form a crystal composition, the proliferation effect reaches about 75%, which is a significant difference, which means that the lactic acid bacteria and the algae fermented liquid There is an additive effect.
將乳酸菌晶體組合物的抗病毒實驗分成六組樣本,分別為: The antiviral experiment of the lactic acid bacteria crystal composition is divided into six groups of samples, namely:
(1)Control-對照組 (1) Control-control group
(2)Virus-攻毒組 (2) Virus-challenge group
(3)四株乳酸菌混合物-攻毒組 (3) Mixture of four lactic acid bacteria-challenge group
(4)藻類萃取物-攻毒組 (4) Algae extract-challenge group
(5)藻類醱酵液-攻毒組 (5) Algae fermented liquid-challenge group
(6)四株乳酸菌+藻類醱酵液結晶體-攻毒組 (6) Four strains of lactic acid bacteria + algae fermented liquid crystals-challenge group
使用vero腎上皮細胞作為模型,以腸病毒71型進行攻毒,實驗分兩種方式進行: Using vero renal epithelial cells as a model, challenge with Enterovirus 71. The experiment was carried out in two ways:
將vero腎上皮細胞種於96孔盤中,50,000cell/well,培養24小時後更換培養基(分別含200μg/ml各樣本與不含樣本),培養4小時後加入腸病毒71型攻毒,24小時後以MTT assay進行vero腎上皮細胞存活率測定。即是分別將(1)Control-對照組、(2)Virus-攻毒組、(3)四株乳酸菌混合物-攻毒組、(4)藻類萃取物-攻毒組、(5)藻類醱酵液-攻毒組、(6)四株乳酸菌 +藻類醱酵液結晶體-攻毒組樣本與vero腎上皮細胞共培養,測試各樣本是否對vero腎上皮細胞具有保護作用,能抵抗病毒的感染。 The vero renal epithelial cells were seeded in 96-well plates, 50,000cell/well, cultured for 24 hours and then replaced the medium (with 200μg/ml samples and no samples respectively), after 4 hours of culture, enterovirus 71 challenge was added, 24 One hour later, the viability of vero renal epithelial cells was determined by MTT assay. That is, (1) Control-control group, (2) Virus-challenge group, (3) four strains of lactic acid bacteria mixture-challenge group, (4) algae extract-challenge group, (5) algae fermentation Liquid-challenge group, (6) four strains of lactic acid bacteria +Algae fermentation liquid crystals-the challenge group samples are co-cultured with vero renal epithelial cells to test whether each sample has a protective effect on vero renal epithelial cells and can resist virus infection.
將vero腎上皮細胞種於96孔盤中,50,000cell/well,培養24小時後更換培養基(不含樣本),再加入腸病毒71型(分別與200μg/ml各樣本混合或不混合,使病毒與各樣本共培養4小時)攻毒,24小時後以MTT assay進行細胞存活率測定。將病毒與細胞共培養,測試樣本(1)Control-對照組、(2)Virus-攻毒組、(3)四株乳酸菌混合物-攻毒組、(4)藻類萃取物-攻毒組、(5)藻類醱酵液-攻毒組、(6)四株乳酸菌+藻類醱酵液結晶體-攻毒組是否對病毒具有抵抗作用,抑制病毒的感染功效。 Plant vero renal epithelial cells in a 96-well plate, 50,000cell/well, culture for 24 hours, change the medium (without samples), and then add enterovirus 71 (mix or not mix with 200μg/ml each sample respectively to make the virus Co-cultivation with each sample for 4 hours) challenge, 24 hours later, the cell viability was determined by MTT assay. Co-culture the virus and cells, test samples (1) Control-control group, (2) Virus-challenge group, (3) four strains of lactic acid bacteria mixture-challenge group, (4) algae extract-challenge group, ( 5) Whether the algae fermented liquid-challenge group, (6) whether the four lactic acid bacteria + algae fermented liquid crystals-the challenge group has the effect of resisting the virus and inhibiting the infection of the virus.
乳酸菌晶體組合物的抗病毒試驗結果如第6圖所示,顯示(3)四株乳酸菌混合物-攻毒組(**P<0.01)、(4)藻類萃取物-攻毒組(*P<0.05)、(5)藻類醱酵液-攻毒組(**P<0.01)、(6)四株乳酸菌+藻類醱酵液結晶體-攻毒組(***P<0.001)和(2)Virus-攻毒組相比具有顯著對vero腎上皮細胞的保護作用;結果顯示一般乳酸菌經混合後,對於vero腎上皮細胞的保護力已有顯著性,可保護vero腎上皮細胞免於病毒感染;藻類萃取液經醱酵後則能提升細胞的保護力;乳酸菌以藻類醱酵液包覆後之晶體組合物則能提供最高的保護力,達到最高顯著性;對病毒抑制力也具有效果,也以乳酸菌經藻類醱酵液包覆後具有最高抑制效果。 The results of the antiviral test of the lactic acid bacteria crystal composition are shown in Figure 6, showing (3) a mixture of four lactic acid bacteria-challenge group ( ** P<0.01), (4) algae extract-challenge group ( * P< 0.05), (5) Algae fermentation liquid-challenge group ( ** P<0.01), (6) Four strains of lactic acid bacteria + algae fermentation liquid crystals-challenge group ( *** P<0.001) and (2) Virus-challenge group has a significant protective effect on vero renal epithelial cells; the results show that the general lactic acid bacteria have a significant protective effect on vero renal epithelial cells after mixing, and can protect vero renal epithelial cells from virus infection; After the algae extract is fermented, it can enhance the protective power of the cells; the crystalline composition of the lactic acid bacteria coated with the algae fermented liquid can provide the highest protective power and reach the highest significance; it also has an effect on the virus inhibition, and is also effective Lactic acid bacteria have the highest inhibitory effect after being coated with algae fermented liquid.
12名受測者,依照建議用量、建議方式使用乳酸菌晶體組合 物,持續5周,於每周周五進行問卷回饋,以評分方式統計改善效果。 12 subjects used the lactic acid bacteria crystal combination according to the recommended dosage and recommended method It lasts for 5 weeks. Questionnaire feedback will be conducted every Friday, and the improvement effect will be counted by scoring method.
乳酸菌晶體組合物抗發炎試驗,經由問卷調查,其結果如第7圖所示,顯示使用乳酸菌晶體5周,可改善脂漏性皮膚炎及過敏性鼻炎症狀。 The anti-inflammation test of the lactic acid bacteria crystal composition was conducted through a questionnaire survey, and the results are shown in Figure 7. It is shown that the use of lactic acid bacteria crystals for 5 weeks can improve the symptoms of seborrheic dermatitis and allergic rhinitis.
所述之問卷內容如下所示:姓名:使用產品:,本週使用天數:天說明:本週使用產品後之身體狀況,請依據實際情況與感受,在最適當的□中打勾。 The content of the questionnaire is as follows: Name: Product used:, Days of use this week: Days Description: For the physical condition after using the product this week, please tick the most appropriate □ based on the actual situation and feelings.
1.一般生理狀況: 1. General physiological conditions:
身高:體重: Height: Weight:
2.皮膚狀況: 2. Skin condition:
3.抵抗力狀況: 3. Resistance status:
4.身體循環狀況: 4. Body circulation status:
5.腸胃功能狀況: 5. Gastrointestinal function:
每日平均排便次數: Average number of bowel movements per day:
6.肝功能狀況: 6. Liver function status:
7.如有其它身體狀況或想特別說明的,請論述: 7. If you have other physical conditions or want to specify, please discuss:
Claims (21)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW107140879A TWI740073B (en) | 2018-11-16 | 2018-11-16 | Lactic acid bacteria crystal composition capable of promoting intestinal stem cell proliferation, antiviral, anti-inflammatory and anti-allergic effects and preparation method thereof. |
CN201910022855.7A CN111195267B (en) | 2018-11-16 | 2019-01-10 | Lactic acid bacteria crystal composition having effects of promoting intestinal stem cell proliferation, resisting virus, inflammation and allergy, and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW107140879A TWI740073B (en) | 2018-11-16 | 2018-11-16 | Lactic acid bacteria crystal composition capable of promoting intestinal stem cell proliferation, antiviral, anti-inflammatory and anti-allergic effects and preparation method thereof. |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202019395A TW202019395A (en) | 2020-06-01 |
TWI740073B true TWI740073B (en) | 2021-09-21 |
Family
ID=70741800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107140879A TWI740073B (en) | 2018-11-16 | 2018-11-16 | Lactic acid bacteria crystal composition capable of promoting intestinal stem cell proliferation, antiviral, anti-inflammatory and anti-allergic effects and preparation method thereof. |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111195267B (en) |
TW (1) | TWI740073B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI776433B (en) * | 2021-03-22 | 2022-09-01 | 生合生物科技股份有限公司 | Lactobacillus delbrueckii subsp. lactis ldl557 isolate and uses of the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL199781A0 (en) * | 2009-07-09 | 2010-05-17 | Yohai Zorea | Heat resistant probiotic compositions and healthy food comprising them |
CN104203219B (en) * | 2012-02-08 | 2016-03-23 | 约翰内斯堡威特沃特斯兰德大学 | pharmaceutical dosage form |
CN105310080B (en) * | 2015-10-26 | 2018-04-06 | 中山大学 | Probiotic microcapsule and its preparation method and application |
CN108004282B (en) * | 2017-12-01 | 2021-02-05 | 中国农业科学院麻类研究所 | Method for preparing lucid ganoderma sporocarp fermentation product, fermentation product and application thereof |
CN108253059A (en) * | 2018-01-19 | 2018-07-06 | 山东理工大学 | The matched design method of the pre- clamping stress of the first-order gradient main spring of rigidity leaf spring uniform thickness |
-
2018
- 2018-11-16 TW TW107140879A patent/TWI740073B/en active
-
2019
- 2019-01-10 CN CN201910022855.7A patent/CN111195267B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN111195267B (en) | 2022-04-12 |
CN111195267A (en) | 2020-05-26 |
TW202019395A (en) | 2020-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109619593B (en) | Probiotic double-layer microcapsule and preparation method thereof | |
US9649347B2 (en) | Protective effects and application of a Lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury | |
CN108004189A (en) | A kind of compound probiotic lactic acid bacteria powder and preparation method and application | |
CN110141585A (en) | A kind of composite probiotics ferment microbial inoculum and preparation method thereof for adjusting intestinal flora | |
CN105567669B (en) | Probiotic microcapsule preparation and preparation method thereof | |
CN109125525B (en) | Composition for preventing and treating cardiovascular diseases and preparation method and application thereof | |
KR20180070485A (en) | lactic acid bacteria improved stability and preparing method thereof | |
CN111436614A (en) | Probiotics delivery microcapsule based on mushroom soluble dietary fiber and preparation method | |
CN108048349B (en) | Preparation method and application of lactobacillus paracasei N1115 embedded bacteria powder | |
TWI740073B (en) | Lactic acid bacteria crystal composition capable of promoting intestinal stem cell proliferation, antiviral, anti-inflammatory and anti-allergic effects and preparation method thereof. | |
WO2020057451A1 (en) | Method for preparing compositions for treating hair loss | |
CN114916675A (en) | Water-in-oil-in-water type multiple emulsion gel bead for improving survival rate of probiotics, preparation method and application | |
CN113679048A (en) | High-activity probiotic freeze-dried powder for adjusting balance of intestinal flora of infants | |
KR102004204B1 (en) | lactic acid bacteria improved stability and preparing method thereof | |
CN107034159B (en) | Pathogenic bacteria antagonist and application thereof | |
CN105274032A (en) | Lactobacillus reuteri antagonizing Campylobacter jejuni and inhibiting flaA gene expression of Campylobacter jejuni | |
KR101924048B1 (en) | Method for manufacturing fermentation mixture of dietary fiber and lactic acid bacteria | |
CN102396703A (en) | Lactobacillus composition with effect of preventing children hand-foot-mouth disease and preparation and application thereof | |
CN101328471B (en) | Bifidobacterium adolesentis grx066, and use thereof | |
JPWO2020158737A1 (en) | A probiotic composition imparting storage stability and gastric fluid decomposition resistance stability. | |
JP3222391U (en) | Coating structure of plant fermentation broth | |
TWM620232U (en) | Crystal microparticle structure of compound lactic acid combined with natural herb extract | |
CN116478890B (en) | Lactobacillus casei for regulating high blood sugar level, preparation and application thereof | |
CN117159598B (en) | Application of lactobacillus plantarum Lp18 in preparation of immunity-enhancing medicines or health-care foods and products | |
RU2491331C1 (en) | Bifidobacterial and lactobacillary consortium for preparing bacterial preparations and dietary supplements for correcting gastrointestinal microflora in children under age of three, and method for preparing it, dietary supplement and bacterial preparation for treating dysbiotic gastrointestinal conditions in children under age of three |